FDA DEVICE FACTS
Accuro 3S
Rivanna Medical, Inc.
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
The Accuro 3S is a diagnostic ultrasound imaging system for use by qualified and trained healthcare professionals. Accuro 3S is intended to be used in a hospital or medical clinic environment at the point of care.
Accuro 3S supports B -mode imaging and a SpineNav -AI™ image processing software. Accuro 3S clinical applications include: musculoskeletal conventional and superficial, and guidance for needle placement. A typical examination using Accuro 3S is guidance of neuraxial anesthesia.
SafeTrack™ is intended to provide healthcare professionals with visual tools for magnetic tracking of a needle with respect to ultrasound image data in musculoskeletal conventional and superficial applications.
Comparison to Predicate Device(s):
Accuro 3S is substantially equivalent to the predicate device in terms of technological characteristics and safety and effectiveness.
The Accuro 3S system is identical to the predicate device Accuro 3S (K243937) but with the addition of the SafeTrack needle guidance technology. The SafeTrack technology is similar to the Pinpoint GT technology on the reference device Site -Rite 6 (K142443). Both technologies possess a probe with embedded magnetic sensors. In both technologies, the magnetic sensors detect a magnetic signal emitted by the needle and use software to overlay a representation of the needle tip and trajectory on the ultrasound display screen. Both technologies are intended to provide healthcare professionals with visual tools for magnetic tracking of a needle with respect to ultrasound image data. The differences between SafeTrack and Pinpoint GT technology include implementations on different probe geometries.
Differences in design between the Accuro 3S and predicate device do not raise any new issues related to safety or effectiveness.
Summary of Non-Clinical Tests:
The Accuro 3S has been evaluated for acoustic output, cleaning/disinfection and electrical, thermal, mechanical, and EMC safety. The device has been found to conform to applicable medical device safety standards. Patient contact materials are biocompatible.
Validation testing was performed to ensure that Accuro 3S meets the requirements of the intended end users for specified clinical applications.
Assurances of quality were further established by employing the following elements of product design and development in accordance with 21 CFR 820 and ISO 14971:2019:
• Risk analysis
• Requirements development
• Design reviews
• System validation including accuracy and performance validation
• Software verification
• Hardware verification
• Safety compliance verification
Accuro 3S complies with the following FDA guidance and recognized standards:
• Marketing Clearance of Diagnostic Ultrasound Systems and Transducers - Guidance for Industry and Food and Drug Administration Staff, issued on February 21, 2023
• IEC 60601-1 Edition 3.2 2020-08, Medical Electrical Equipment - Part 1: General Requirements for Basic Safety and Essential Performance. [19-49]
• IEC 60601-1-2 Edition 4.1 2020 -09, Medical Electrical Equipment - Part 1-2: General Requirements for Basic Safety and Essential Performance - Collateral Standard: Electromagnetic Disturbances - Requirements and Tests. [19-36]
• IEC 60601-1-6 Edition 3.2 2020 -07, Medical Electrical Equipment – Part 1-6: General Requirements for Basic Safety and Essential Performance – Collateral Standard: Useability. [5-132]
• IEC 60601-2-37 Edition 2.1 2015, Medical Electrical Equipment – Part 2-37: Particular Requirements for the Safety of Ultrasonic Medical Diagnostic and Monitoring Equipment. [12-293]
• IEC 62304, Edition 1.1 2015-06, Medical Device Software – Software Life Cycle Processes. [13-79]
• IEC 62366 -1 Edition 1.1 2020 -06, Medical devices - Part 1: Application of Usability Engineering to Medical Devices. [5-129]
• IEC 62359 Edition 2.1 2017 -09, Ultrasonics - Field Characterization – Test Methods for the Determination of Thermal and Mechanical Indices Related to Medical Diagnostic Ultrasonic Fields. [12 - 316]
• ISO 10993-1 Fifth edition 2018, Biological Evaluation of Medical Devices -Part 1: Evaluation and Testing Within a Risk Management Process. [2-258]
• ISO 14971 Third edition 2019-12, Application of Risk Management to Medical Devices. [5-125]
• NEMA UD 2 -2004 (R2009), Acoustic Output Measurement Standard for Diagnostic Ultrasound Equipment Revision 3. [12-105]
• NEMA PS 3.1 - 3.20e, Digital Imaging and Communications in Medicine (DICOM) Set. [12-352]
• AAMI TIR69:2017(R2020), Technical Information Report Risk management of radio -frequency wireless coexistence for medical devices and systems. [19-22]
Summary of Clinical Tests:
The subject of this premarket submission, Accuro 3S, did not require clinical studies to support the determination of substantial equivalence.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。